The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Alzheimer's disease drug development pipeline: 2018
Open accessAbstract
Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease‐modifying agent trials and 17 disease‐modifying agent trials in phase II. Twenty‐one trials of disease‐modifying agents in phase II did not require biomarker confirmation for AD at trial entry. Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of additional pathogenic mechanisms have been described, possibly overlapping with Aβ plaques and NFT formation or induced by them, including inflammation, oxidative damage, iron deregulation, and cholesterol metabolism blood-brain barrier (BBB) dysfunction or α-synuclein toxicity.9-13”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Moreover, the literature review reveals that only a single cholinesterase inhibitor is in Phase II and Phase III clinical trials, for AD management [147,148].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Research works printed but not linked: 1
- Lombardo I., 2017, Results from the phase 3 MINDSET STUDY: a global, double‐blind, placebo‐controlled study of intepirdine in mild‐to‐moderate Alzheimer's disease
Cited by
Sorted by citations
Items 401–500 of 701
Health economic modeling for Alzheimer's disease: Expert perspectives
Landeiro, F., Morton, J., Gustavsson, A., Potashman, M. H., Lecomte, P., Belger, M. A., Thompson, R., Roncancio‐Diaz, E., Jhuti, G. S., Butler, C., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12360 · Cited by 15
Vilela, A. F. L., Seidl, C., Lima, J. M., & Cardoso, C. L. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.03.012 · Cited by 16
Jang, B.-G., Lee, J., Choi, B., Koh, Y. H., & Kim, M.-J. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112185 · Cited by 15
Should we move dementia research funding from a cure to its care?
Wong, G. H. Y., & Knapp, M. R. J. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1735364 · Cited by 15
Oxtoby, N. P., Shand, C., Cash, D. M., Alexander, D. C., & Barkhof, F. (2022) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2022.660581 · Cited by 14
Shi, J., Zhou, Y. M., Wang, K., Ma, Q., Wei, R., Li, Q., Zhao, Y., Qiao, Z., Liu, S., Leng, Y., et al. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02666-6 · Cited by 14
MDSVDNV: predicting microbe–drug associations by singular value decomposition and Node2vec
Tan, H., Zhang, Z., Liu, X., Chen, Y., Yang, Z., & Wang, L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1303585 · Cited by 14
Hojjati, S. H., Butler, T., de Leon, M. J., Gupta, A. K., Nayak, S., Luchsinger, J. A., Razlighi, Q. R., & Chiang, G. C.-Y. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.01.005 · Cited by 18
Quartey, M. O., Nyarko, J. N. K., Pennington, P. R., Heistad, R. M., Chaharyn, B. M., Wei, Z.-L., Bainbridge, D., Baker, G., & Mousseau, D. (2019) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2019.02.083 · Cited by 11
An integrative review of system-level factors influencing dementia detection in primary care
Romano, R. R., Carter, M. A., Anderson, A. R., & Monroe, T. B. (2019) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000230 · Cited by 14
Use of Biomarkers in Ongoing Research Protocols on Alzheimer’s Disease
Canevelli, M., Remoli, G., Bacigalupo, I., Valletta, M., Blasi, M. T., Sciancalepore, F., Bruno, G., Cesari, M., & Vanacore, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030068 · Cited by 14
α-Synuclein and tau, two targets for dementia
Silva, M., Caro, V., Guzmán, C., Perry, G. L., Areche, C., & Cornejo, A. (2020) · Studies in natural products chemistry · doi:10.1016/b978-0-12-819483-6.00001-1 · Cited by 15
Thunell, J. A., Chen, Y., Joyce, G., Barthold, D., Shekelle, P., Brinton, R. D., & Zissimopoulos, J. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12175 · Cited by 15
Pachón-Angona, I., Martin, H., Daniel, S., Moraleda, I., Bonet, A., Wnorowski, A., Maj, M., Jóźwiak, K., Iriepa, I., Refouvelet, B., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207652 · Cited by 14
Choi, Y., Hong, Y., & Kyung, Y. (2021) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.21.384 · Cited by 14
Annadurai, N., Malina, L., Salmona, M., Diomede, L., Bastone, A., Cagnotto, A., Romeo, M., Šrejber, M., Berka, K., Otyepka, M., et al. (2021) · FEBS Journal · doi:10.1111/febs.16270 · Cited by 14
Kurakin, A. V., & Bredesen, D. E. (2020) · Aging · doi:10.18632/aging.103883 · Cited by 15
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development
Chowdhury, S. R., Xie, F., Gu, J., & Fu, L. (2019) · Pharmaceutical Fronts · doi:10.1055/s-0039-1698405 · Cited by 13
Ayan, E. B., DeMirci, H., Serdar, M. A., Palermo, F., & Baykal, A. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612819 · Cited by 15
Kuhn, A. J., Chan, K., Sajimon, M., Yoo, S., Serrão, V. H. B., Lee, J., Abrams, B. S., Nowick, J. S., Uversky, V. N., Wheeler, C. J., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11511 · Cited by 14
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 13
Venter, J., Pérez, C., van Otterlo, W. A. L., Martı́nez, A., & Blackie, M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.049 · Cited by 13
Hausner, L., Frölich, L., Arnim, C. A. F. V., Bohlken, J., Dodel, R. C., Otto, M., Rapp, M. A., Schulz, J. B., Supprian, T., Wollmer, M. A., et al. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-01007-7 · Cited by 13
Comparison of polypeptides that bind the transferrin receptor for targeting gold nanocarriers
McQuaid, C., Halsey, A. M., Dubois, M., Romero, I. A., & Male, D. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252341 · Cited by 15
S, G. S., Raghu, C. H., & Fayaz, S. M. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210920120612 · Cited by 13
Tian, Z., Wang, P., Huang, K., Yu, J. Z., Zhang, M., Liu, Y., Zhao, H., Zhu, B., Huang, X., & Tong, Z. (2023) · Lasers in Medical Science · doi:10.1007/s10103-022-03692-z · Cited by 14
Marine bacterial extracts as a new rich source of drugs against Alzheimer’s disease
Zhu, B., Li, Z., Qian, P., & Herrup, K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14847 · Cited by 13
Hasselbalch, H. C., Skov, V., Kjær, L., Sørensen, T. L., Ellervik, C., & Wienecke, T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01877-3 · Cited by 13
Lee, H., & Kim, E. Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01268-5 · Cited by 14
Using machine intelligence to uncover Alzheimer’s disease progression heterogeneity
Qorri, B., Tsay, M., Agrawal, A., Au, R., & Gracie, J. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00026 · Cited by 13
An Integrated Molecular Atlas of Alzheimer’s DiseasePreprint
Wörheide, M. A., Krumsiek, J., Nataf, S., Nho, K. T., Greenwood, A. K., Wiley, J. C., Willruth, L.-L., Wu, T., Bellur, O., Marella, B., et al. (2021) · medRxiv · doi:10.1101/2021.09.14.21263565 · Cited by 12
Díaz González, M., Buberman, A., Morales, M., Ferrer, I., & Knafo, S. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.683290 · Cited by 12
Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimer’s: A Review
Mehendale-Munj, S., & Patil, P. B. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221228140450 · Cited by 12
Karima, S., Aghamollaii, V., Baram, S. M., Balenci, L., Lanctôt, K. L., Kiss, A., Tafakhori, A., Mahdavi, M., Rajaei, S., Shateri, S., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221026 · Cited by 12
Ashmawy, R. E., Okesanya, O. J., Ukoaka, B. M., Daniel, F. M., Ezedigwe, S. G., Agboola, A. O., Ahmed, M. M., Ogaya, J. B., Amisu, B. O., Adigun, O. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331640 · Cited by 13
Gay, M., Evrard, C., Descamps, F., Carato, P., Renault, N., Coevoet, M., Eddarkaoui, S., Baud, C., Larchanché, P.-E., Buée, L., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.092 · Cited by 14
Kaur, P., Kibat, C., Teo, E., Gruber, J., Mathuru, A. S., & Tolwinski, N. S. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3856 · Cited by 12
A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model
Post, J., Kogel, V., Schaffrath, A., Lohmann, P., Shah, N. J., Langen, K., Willbold, D., Willuweit, A., & Kutzsche, J. (2021) · Molecules · doi:10.3390/molecules26061590 · Cited by 12
Qiao, O., Zhang, X., Zhang, Y., Ji, H., Li, Z., Han, X., Wang, W., Li, X., Wang, J., Liu, C., et al. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00456-9 · Cited by 12
Viel, C., Brandtner, A. T., Weißhaar, A., Lehto, A., Fuchs, M., & Klein, J. (2021) · Pharmaceuticals · doi:10.3390/ph14121218 · Cited by 13
Prakash, P., Lantz, T. C., Jethava, K. P., & Chopra, G. (2019) · Methods and Protocols · doi:10.3390/mps2020048 · Cited by 12
Circularity, psychiatry & biomarkers: The operationalisation of Alzheimer's & stress in research
Fletcher, J. R., & Birk, R. H. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.112553 · Cited by 15
Llorente, P., Martins, S., Sastre, I., Aldudo, J., Recuero, M., Adjaye, J., & Bullido, M. J. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5917187 · Cited by 10
The histone code in dementia: Transcriptional and chromatin plasticity fades away
Bano, D., Salomoni, P., Ehninger, D., & Nicotera, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.014 · Cited by 12
Lyu, D., Li, T., & Lyu, X. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049798 · Cited by 12
Overview about Oral Films in Mental Disorders
Batista, P., Pintado, M., & Oliveira‐Silva, P. (2023) · Pharmaceuticals · doi:10.3390/ph16081063 · Cited by 11
Upīte, J., Kadish, I., van Groen, T., & Jansone, B. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147022 · Cited by 11
Ugbaja, S. C., Appiah‐Kubi, P., Lawal, M. M., Gumede, N. S., & Kumalo, H. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1869099 · Cited by 11
Lye, S., Aust, C. E., Griffiths, L. R., & Fernandez, F. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117332 · Cited by 11
Modelling the value of innovative treatments for Alzheimer’s disease in the United States
Makin, C., Neumann, P. J., Peschin, S., & Goldman, D. P. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1927747 · Cited by 11
Computer-assisted evaluation of plant-derived β-secretase inhibitors in Alzheimer’s disease
Ullah, M. A., Johora, F. T., Sarkar, B., Araf, Y., Ahmed, N., Nahar, A. N., & Akter, T. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-021-00150-3 · Cited by 11
Huang, W., Zeng, F., Gu, Y., Jiang, M., Zhang, X., Yan, X., Kadowaki, T., Mizutani, S., Kashiwazaki, H., Ni, J., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210031 · Cited by 11
Ghazarian, A. L., Haim, T., Sauma, S., & Katiyar, P. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12392 · Cited by 11
Committee on High‐quality Alzheimer's Disease Studies (CHADS) consensus report
Jicha, G. A., Abner, E. L., Arnold, S. E., Carrillo, M. C., Dodge, H. H., Edland, S. D., Fargo, K. N., Feldman, H., Goldstein, L. B., Hendrix, J. A., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12461 · Cited by 11
Nisa, N., Rasmita, B., Arati, C., Uditraj, C., Siddhartha, R., Dinata, R., Bhanushree, B., Bidanchi, R. M., Manikandan, B., Saeed, A.-L., et al. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-25943-4 · Cited by 11
Lee, H. E., Lim, D., Lee, J. Y., Lim, S. M., & Pae, A. N. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0003 · Cited by 11
Shi, L., Buchanan, C. R., Cox, S. R., Hillary, R. F., Marioni, R. E., Campbell, A., Hayward, C., Stolicyn, A., Whalley, H. C., Harris, M. A., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12240 · Cited by 10
Srinivasan, M., Lahiri, N. K., Thyagarajan, A., Witek, E., Hickman, D. L., & Lahiri, D. K. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.04.004 · Cited by 11
Akawa, O. B., Subair, T. I., Soremekun, O. S., Olotu, F. A., & Soliman, M. E. S. (2021) · RSC Advances · doi:10.1039/d0ra10459k · Cited by 11
García‐Arriaza, J., Marín, M. Q., Merchán‐Rubira, J., Mascaraque, S. M., Medina, M., Ávila, J., Hernández, F., & Estéban, M. (2020) · Vaccines · doi:10.3390/vaccines8010127 · Cited by 11
Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil
Sikora, J., Podsiedlik, M., Pietras, T., Kosmalski, M., Matłoka, M., Moszczyński-Pętkowski, R., Wieczorek, M., & Markowicz-Piasecka, M. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1818739 · Cited by 8
Who funds Alzheimer's disease drug development?
Cummings, J. L., Bauzon, J. S., & Lee, G. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12185 · Cited by 9
Self-citationKim, S., Nam, Y., Ham, M.-J., Park, C., Moon, M., & Yoo, D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.682308 · Cited by 10
Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
Yu, J. C., Hlávka, J. P., Joe, E., RICHMOND, F. J. R., & Lakdawalla, D. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12280 · Cited by 9
Bojić, T., Senćanski, M., Perović, V., Milićević, J. S., & Glišić, S. (2022) · Molecules · doi:10.3390/molecules27092626 · Cited by 10
Aygün, M., Celepci, D. B., Akgül, Ö., & Pabuççuoğlu, V. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139094 · Cited by 10
Canevelli, M., Bacigalupo, I., Gervasi, G., Lacorte, E., Massari, M., Mayer, F., Vanacore, N., & Cesari, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00282 · Cited by 10
Monteiro, K. L. C., Alcântara, M. G. D. S., de Aquino, T. M., & da Silva‐Júnior, E. F. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200414164038 · Cited by 10
He, Y., Xiao, G., Yu, G., Song, Q., Zhang, H., Liu, Z., Tan, Z., & Deng, Y. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02725-6 · Cited by 11
Wnt Signaling Rescues Amyloid Beta-Induced Gut Stem Cell Loss
Kaur, P., Chua, E. H. Z., Lim, W. K., Liu, J., Harmston, N., & Tolwinski, N. S. (2022) · Cells · doi:10.3390/cells11020281 · Cited by 10
Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease
Forester, B. P., Patrick, R. E., & Harper, D. G. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.2332 · Cited by 9
Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders
Sahara, N., & Higuchi, M. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13711 · Cited by 9
Bayraktar, G., Bartolini, M., Bolognesi, M. L., Erdoğan, M. A., Armağan, G., Bayır, E., Şendemir, A., Bagetta, D., Alcaro, S., & Alptüzün, V. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202300575 · Cited by 9
Doumar, H., Mostafi, H. E., Elhessni, A., Touhami, M. E., & Mesfioui, A. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.12.011 · Cited by 9
Large language models for Alzheimer's disease drug discovery
Alkam, T., Tarshizi, E., & Benschoten, A. H. V. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251346890 · Cited by 9
Sex differences in vulnerability to tau pathology: Impact on cognitive decline
Zeighami, Y., Tremblay, C., & Dadar, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70634 · Cited by 10
Son, S. H., Do, J. M., Yoo, J.-N., Lee, H. W., Kim, N. K., Yoo, H., Gee, M. S., Kim, J.-H., Seong, J., Inn, K., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105022 · Cited by 9
Learning Transition Times in Event Sequences: The Temporal Event-Based Model of Disease Progression
Wijeratne, P. A., Alexander, D. C., & Initiative, A. D. N. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-78191-0_45 · Cited by 11
Disease modification is not all — we need symptomatic therapies for Alzheimer disease
Cummings, J. L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00591-9 · Cited by 9
Self-citationPatient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease
Asiamah, E. A., Guo, R., Kong, D., Feng, B., He, J., Zhang, W., Liu, X., Du, X., Ma, Z., Liu, B., et al. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0065 · Cited by 9
Atkinson-Dell, R., & Mohamet, L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_15 · Cited by 10
ROSETTA-informed design of structurally stabilized cyclic anti-amyloid peptides
Est, C. B., Mangrolia, P., & Murphy, R. M. (2019) · Protein Engineering Design and Selection · doi:10.1093/protein/gzz016 · Cited by 9
Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach
Cummings, J. L. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000507569 · Cited by 9
Self-citationGenoRisk: A polygenic risk score for Alzheimer's disease
Dickson, S. P., Hendrix, S. B., Brown, B. L., Ridge, P. G., Nicodemus‐Johnson, J., Hardy, M. L., McKeany, A. M., Booth, S. B., Fortna, R. R., Kauwe, J. S. K., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12211 · Cited by 8
[Metabolic syndrome and magnesium].
Kumeda, Y., & Inaba, M. (2005) · PubMed · Cited by 9
Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases
Zhang, L., Sun, H., Chen, Y., Wei, M., Lee, J., Li, F., & Ling, D. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1696 · Cited by 8
Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer’s Disease: A Systematic Review
Premkumar, T., & Sajitha Lulu, S. (2022) · Neurochemical Journal · doi:10.1134/s1819712422040183 · Cited by 8
Rodriguez‐Hernandez, M. A., Alemany, I., Olofsson, J., Diaz‐Galvan, P., Němý, M., Westman, E., Barroso, J., Ferreira, D., & Cedrés, N. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105534 · Cited by 10
Interpreting cognitive decline in the face of cognitive reserve
Bialystok, E., Anderson, J. A. E., & Grundy, J. G. (2018) · Linguistic Approaches to Bilingualism · doi:10.1075/lab.18040.bia · Cited by 9
Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 9
Isla, A. G., Balleza‐Tapia, H., & Fisahn, A. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113743 · Cited by 9
Danao, K. R., Kodape, Y., Mahapatra, D. K., Borikar, S. P., & Karande, N. A. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.131107 · Cited by 8
Oligonucleotides: A novel area of interest for drug delivery in neurodegenerative diseases
Alharbi, K. S., Shaikh, M. A. J., Afzal, O., Altamimi, A. S. A., Almalki, W. H., Kazmi, I. A., Al-Abbasi, F. A., Alzarea, S. I., Babu, M. R., Singh, S. K., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103849 · Cited by 8
He, W., Tu, M., Du, Y., Li, J., Pang, Y., & Dong, Z. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200003 · Cited by 8
Ang, S., Zhang, X., Hong, J., Xue, K., Li, J., Du, X., Gao, Y., Wang, X., Li, X., Chen, B., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03788-4 · Cited by 9
Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults
Longhurst, J. K., Cummings, J. L., John, S. E., Poston, B., Rider, J. V., Salazar, A. M., Mishra, V. R., Ritter, A. R., Caldwell, J., Miller, J. B., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.1 · Cited by 7
Self-citationPCSK6 exacerbates Alzheimer's disease pathogenesis by promoting MT5-MMP maturation
Xu, M., Li, J., Xia, L., Du, Y., Wu, B., Shi, X., Tian, N., Pang, Y., Yi, L., Chen, M., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114688 · Cited by 8
Lin, Y.-L., Yao, T., Wang, Y.-W., Lu, J.-H., Chen, Y., Wu, Y., Qian, X.-G., Liu, J., Fang, L.-X., Zheng, C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.039 · Cited by 8
The KLDpT activation loop motif is critical for MARK kinase activity
Sonntag, T., Moresco, J. J., Yates, J. R., & Montminy, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225727 · Cited by 6
Metadata
- Authors
- Cummings, J., Lee, G., Ritter, A., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Global Alzheimer's Platform Foundation (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 195-214
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6021548
- OpenAlex
- W2918066696
- Cited by
- 697
- References
- 48
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 39 · 2023: 22 · 2022: 55 · 2021: 138 · 2020: 177 · 2019: 170 · 2018: 42
- FWCI
- 91.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, disease-modifying therapy, amyloid biomarkers, prodromal Alzheimer's disease, preclinical Alzheimer's disease, neuropsychiatric symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
